2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugs
23rd December 2024 Uncategorised 0While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts of the new class of cardiometabolic medicines have been consistently hamstrung by manufacturing and supply constraints. That said, “positive signals” are emerging around the future of GLP-1 supply, analysts at ZS opined.
More: 2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugs
Source: fierce